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Objectives—To evaluate the effectiveness of cervical pessary for preventing sponta-
neous preterm birth (SPTB) in singleton gestations with a second trimester short
cervix.
Methods—Electronic databases were searched from their inception until February
2016. We included randomized clinical trials (RCTs) comparing the use of the cer-
vical pessary with expectant management in singletons pregnancies with transvaginal
ultrasound cervical length (TVU CL) 25 mm. The primary outcome was inci-
dence of SPTB <34 weeks. The summary measures were reported as relative risk
(RR) with 95% conﬁdence interval (CI).
Results—Three RCTs (n5 1,420) were included. The mean gestational age (GA)
at randomization was approximately 22 weeks. The Arabin pessary was used as
intervention in all three trials, and was removed by vaginal examination at approxi-
mately 37 weeks. Cervical pessary was not associated with prevention of SPTB<37
(20.2% vs 50.2%; RR 0.50, 95% CI 0.23 to 1.09), <34, <32, and <28 weeks, com-
pared to no pessary. No differences were found in the mean of GA at, interval from
randomization to delivery, incidence of preterm premature rupture of membranes
and of cesarean delivery, and in neonatal outcomes. The Arabin pessary was associ-
ated with a signiﬁcantly higher risk of vaginal discharge.
Conclusions—In singleton pregnancies with a TVU CL 25mm at 200–246 weeks,
the Arabin pessary does not reduce the rate of spontaneous preterm delivery or
improve perinatal outcome. Individual patient data meta-analysis may clarify
whether cervical pessary may be beneﬁcial in subgroups, such as only singleton ges-
tations without prior SPTB or by different CL cutoffs.
Key Words—cerclage; cervix; meta-analysis; obstetrics; preterm birth; review;
transvaginal ultrasound cervix
S pontaneous preterm birth (SPTB) remains the number onecause of perinatal mortality in many countries, including theUnited States.1 In singleton gestations, a short cervical length
(CL) on transvaginal ultrasound (TVU) has been shown to be a
better predictor of SPTB than digital examination and fetal
ﬁbronectin.2
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ORIGINAL RESEARCH
The cervical pessary is a silicone device that has
been used to prevent SPTB. The leading hypotheses for
its mechanisms are two: that the pessary helps to keep
the cervix closed, and that the pessary changes the incli-
nation of the cervical canal so that the pregnancy weight
is not directly above the internal os. The efﬁcacy of cervi-
cal pessary has been assessed in several populations,
including singleton gestations with short CL,3 unselected
twins,4,5 twins with a short CL,6 and triplet pregnancies.7
Several randomized clinical trials (RCTs) have been
published3–6 and several are ongoing.7–9 However, no
consensus on the use of cervical pessary in pregnancy or
guidelines for management have been assessed.
The aim of this systematic review with meta-
analysis was to evaluate the effectiveness of cervical
pessary for preventing SPTB in singleton gestations
with a short cervix in the second trimester.
Materials and Methods
Search Strategy
The review protocol was established by two investiga-
tors (G.S., V.B.) prior to commencement and was reg-
istered with the PROSPERO International Prospective
Register of Systematic Reviews (registration No. CRD
42016035938).
Two authors (G.S., A.C.) identiﬁed trials by search-
ing independently the electronic databases MEDLINE,
Scopus, ClinicalTrials.gov, the PROSPERO Interna-
tional Prospective Register of Systematic Reviews,
EMBASE, and the Cochrane Central Register of Con-
trolled Trials with the use of a combination of the fol-
lowing text words: “pessary,” “cervical,” “cervix,”
“cervical length,” “preterm birth,” “randomized trial,”
“preterm delivery,” “prematurity” “clinical,” and “insuf-
ﬁciency” from inception of each database until February
2016. Agreement regarding potential relevance was
reached by discussion with a third reviewer (V.B.).
Study Selection
All RCTs comparing the use of cervical pessary (ie,
intervention group) with expectant management (ie,
control group) for prevention of SPTB in singleton
pregnancies with short CL, deﬁned as TVU CL
25mm, were included in the meta-analysis. Trials on
multiple pregnancies were excluded. Quasi-randomized
trials (ie, trials in which allocation was done on the basis
of a pseudo-random sequence; eg, odd/even hospital
number or date of birth, alternation) were also excluded.
Data Extraction and Risk of Bias Assessment
The risk of bias in each included study was assessed by
using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions.10 Seven do-
mains related to risk of bias were assessed in each
included trial since there is evidence that these issues are
associated with biased estimates of treatment effect: 1)
random sequence generation; 2) allocation conceal-
ment; 3) blinding of participants and personnel; 4)
blinding of outcome assessment; 5) incomplete out-
come data; 6) selective reporting; and 7) other bias.
Review authors’ judgments were categorized as “low
risk,” “high risk,” or “unclear risk” of bias.10
Two authors (G.S., A.C.) independently assessed
inclusion criteria, risk of bias, and data extraction. Dis-
agreements were resolved by consensus through dis-
cussion. Data from each eligible study were extracted
without modiﬁcation of original data onto custom-
made data-collection forms. Differences were reviewed
and further resolved by common review of the entire
process.
Primary and secondary outcomes were deﬁned be-
fore data extraction. The primary outcome was incidence
of SPTB <34 weeks. The secondary outcomes were
SPTB <37,< 32, and <28 weeks; PTB (either sponta-
neous or indicated)< 34 weeks; mean gestational age
(GA) at delivery (in weeks); mean latency (ie, interval
from randomization to delivery) (in days); incidence of
preterm premature rupture of membranes; incidence of
cesarean delivery (CD); maternal side effects (ie, vaginal
discharge, bacterial vaginosis); and neonatal outcomes
including mean birth weight (in grams), incidence of
low birth weight (ie, birth weight< 2500 grams),
necrotizing enterocolitis, respiratory distress syndrome,
intraventricular hemorrhage (grade 3 or 4), admission to
neonatal intensive care unit, fetal mortality (ie, fetal
death after 20 weeks), neonatal mortality (ie, death of a
live-born baby within the ﬁrst 28 days of life), and peri-
natal death (ie, either fetal mortality or neonatal
mortality).
Data Analysis
The data analysis was completed independently by two
authors (G.S., S.X.) using Review Manager 5.3 (The
Nordic Cochrane Centre, Cochrane Collaboration,
Copenhagen).10 The completed analyses were then
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compared, and any difference was resolved with review
of the entire data and independent analysis. Between-
study heterogeneity was explored using the I2 statistic,
which represents the percentage of between-study varia-
tion that is due to heterogeneity rather than chance. A
value of 0% indicates no observed heterogeneity,
whereas I2 values of 50% indicate a substantial level of
heterogeneity. A ﬁxed-effects model was used if substan-
tial statistical heterogeneity was not present. On the con-
trary, if there was evidence of signiﬁcant heterogeneity
between studies included, a random-effects model was
used.10 We planned subgroup analyses of singleton ges-
tations without prior SPTB and singleton gestations
with prior SPTB, and by TVU CL cutoffs of 20mm,
and 15mm, respectively. We planned to assess poten-
tial publication biases by using Begg’s and Egger’s tests.
Tests for publication bias were carried out only when
the total number of publications included for each out-
come was more than 10.
The summary measures were reported as relative
risk (RR) or as mean differences (MD) with 95% conﬁ-
dence interval (CI); P value< 0.05 was considered stat-
istically signiﬁcant.
The meta-analysis was reported following the Pre-
ferred Reporting Item for Systematic Reviews and Meta-
analyses (PRISMA) statement.11
Results
Study Selection and Study Characteristics
Figure 1 shows the ﬂow diagram (PRISMA template) of
information through the different phases of the review.
Supplemental ﬁle S1 shows the full electronic search
from the major database (ie, MEDLINE).
Six studies were assessed for eligibility.3–6,12,13 Three
trials including multiple pregnancies were excluded.4–6
Three RCTs were therefore included in the meta-analy-
sis.3,12,13 The overall risk of bias of the included trials
was low (Figure 2). All studies had a low risk of bias in
“random sequence generation,” “incomplete outcome
data,” and “selective reporting.” Adequate methods for
allocation of women were used. Blinding was considered
not feasible methodologically given the intervention, and
none of the included studies was double-blind. Publica-
tion bias could not be assessed given the small (<10)
number of studied included.
All trials enrolled only singleton gestations with
TVU CL 25mm.3,12 Women with major fetal
abnormalities, painful regular uterine contractions, active
vaginal bleeding, ruptured membranes, placenta previa,
history of a cone biopsy, and a cerclage in situ were
excluded. The mean GA at randomization was about 22
weeks in the 3 studies. The pessary was removed by a
simple vaginal examination at about 37 weeks, or earlier
if the women presented with rupture of membranes, vag-
inal bleeding, or painful uterine contractions. Only Goya
et al6 did not remove the pessary in case of rupture of
membranes. However, in this trial only 3 women in the
cervical pessary group developed premature rupture of
Figure 1. Flow diagram of studies identiﬁed in the systematic review.
(Prisma template [Preferred Reporting Item for Systematic Reviews
and Meta-analyses]). RCTs, randomized clinical trials.
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membranes. All 3 studies used the Arabin pessary (Con-
formite Europeenne marking 0482) (Table 1). Regard-
ing the use of progesterone, 2 trials did not use it.3,12 In
Nicolaides et al, 359 women (38.5%), from both the
pessary and control groups, with CL 15mm at ran-
domization or subsequent visit, received 200mg vaginal
Table 1. Descriptive Data of the Included Trials
Goya 20123 Hui 201312 Nicolaides 201613
Study location Spain China Multicentera
Number of centers 5 1 16
Months of study 36 29 53
Sample size 380 (190 vs 190) 108 (53 vs 55) 932 (465 vs 467)
GA at randomization (range) 200–236 200–246 200–246
GA at randomization (weeks) 22.260.9 vs 22.460.9 21.96 3.5 vs 21.76 3.3 23.4 (22.6–24.3) vs 23.6 (22.7–24.4)
Inclusion criteria Singletons with short CL Singletons with short CL Singletons with short CL
Deﬁnition of short CL TVU CL 25mm TVU CL 25mm TVU CL 25mm
Use of vaginal progesterone 0/190 vs 0/190 0/53 vs 0/55 177/465 (38.1%) vs 182/467 (39.0%)b
Women with prior SPTB 21/190 (11.1%)
vs 20/190 (10.5%)
3/53 (5.7%) vs
6/55 (10.9%)
70/465 (15.1%) vs 84/467 (18.0%)
Use of 17P in women with prior SPTB 0/190 vs 0/190 0/53 vs 0/55 0/465 vs 0/467
Cerclage for cervical shortening 0/190 vs 0/190 0/53 vs 0/55 2/465 (0.4%) vs 5/467 (1.1%)
Type of cervical pessary Arabin Arabin Arabin
Primary outcome SPTB< 34 weeks SPTB< 34 weeks SPTB< 34 weeks
Data are presented as total number (number in the pessary group vs number in the control group)
CL, cervical length; GA, gestational age; SPTB, spontaneous preterm birth; TVU, transvaginal ultrasound; 17P, 17-hydroxyprogesterone
caproate.*Composite perinatal outcome, deﬁned as at least one of the following: stillbirth, periventricular leucomalacia, severe respiratory
distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, proven sepsis, and neonatal
death.
aEngland, Germany, Slovenia, Portugal, Italy, Belgium, Albania, Chile and Australia.
bVaginal progesterone 200mg daily for TVU CL 15mm.
Figure 2. Assessment of risk of bias. A, Summary of risk of bias for each trial; plus sign: low risk of bias; minus sign: high risk of bias; question
mark: unclear risk of bias. B, Risk-of-bias graph about each risk-of-bias item presented as percentages across all included studies.
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suppository daily containing natural progesterone up to
336 weeks’ gestation.13 None of the three trials used 17-
hydroxyprogesterone caproate as prophylactic treatment
for women with prior SPTB.
Synthesis of Results
Table 2 shows the pooled results for the primary and
the secondary outcomes. Out of the 1420 singleton ges-
tations included, 708 (49.8%) were randomized to the
pessary group, and 712 (50.2%) to the expectant man-
agement group (ie, control group). Use of a cervical pes-
sary in singleton gestations with a TVU CL 25mm
starting at 200–246 weeks was not associated with pre-
vention of SPTB <37 (20.2% versus 50.2%; RR 0.50,
95% CI 0.23 to 1.09),< 34 (10.2% versus 14.6%; RR
0.71, 95% CI 0.21 to 2.42; Figure 3),< 32 (9.9% versus
7.5%; RR 1.32, 95% CI 0.87 to 2.01) and <28 weeks
(4.4% versus 4.8%; RR 0.70, 95% CI 0.18 to 2.67) com-
pared to no pessary. No differences were found in the
incidence of PTB <34 weeks (11.2% versus 15.3%; RR
0.74, 95% CI 0.23 to 2.38); in the mean of GA at deliv-
ery (MD 1.63 weeks, 95% CI 20.82 to 4.07); interval
from randomization to delivery (MD 11.91 days, 95%
CI26.97 to 30.79); in the incidence of preterm prema-
ture rupture of membranes (3.7% versus 10.2%; RR
0.39, 95% CI 0.09 to 1.71) and of CD (21.6% versus
21.1%; RR 1.02, 95% CI 0.70 to 1.51); and in the neona-
tal outcomes including birth weight (MD -113.00 grams,
95% CI 2364.95 to 138.95), low birth weight (20.6%
versus 18.4%; RR 1.15, 95% CI 0.88 to 1.49), necrotiz-
ing enterocolitis (0.9% versus 0.8%; RR 0.95, 95% CI
0.11 to 8.07), respiratory distress syndrome (5.4% versus
6.9%; RR 0.80, 95% CI 0.22 to 3.00), intraventricular
hemorrhage (1.3% versus 0.8%; RR 0.94, 95% CI 0.15
to 6.04), admission to neonatal intensive care unit
(14.1% versus 14.4%; RR 1.02, 95% CI 0.73 to 1.42),
fetal mortality (1.1% versus 0.7%; RR 1.61, 95% CI 0.53
to 4.88), neonatal mortality (1.1% versus 0.8%; RR 1.32,
95% CI 0.48 to 3.65), and perinatal death (2.3% versus
1.5%; RR 1.44, 95% CI 0.69 to 3.04) comparing the
intervention group with the control group. The Arabin
pessary was associated with a signiﬁcantly higher risk of
vaginal discharge (37.3% versus 18.0%; RR 2.12, 95%
CI 1.84 to 2.44) but not of bacterial vaginosis (25.8%
versus 22.8%; RR 1.14, 95% CI 0.95 to 1.36). Planned
subgroup analyses were not feasible, as data were not
reported by prior SPTB or not, or by other TVU CL
cutoffs.
Comment
Main Findings
This meta-analysis from 3 high-quality RCTs, including
a total of 1420 singleton gestations with a short TVU
CL 25mm, showed that cervical pessary use did not
prevent SPTB or improve perinatal outcome. We also
found an increased risk of vaginal discharge in women
who received the pessary. Our meta-analysis included
level 1 data from 3 appropriately powered, well-designed
RCTs. Pooled data available to date point to a lack of
efﬁcacy of the Arabin pessary in singleton pregnancies
with short cervix.
Comparison With Existing Literature
Our data do not support earlier ﬁndings of a Cochrane
review of only 1 trial,3 including 380 women, which
showed a beneﬁcial effect of cervical pessary in reducing
spontaneous preterm deliveryin singleton gestations
with a TVU CL25mm.14
Strengths and Limitations
One of the strengths of our study is inclusion of only
RCT data on prevention of SPTB in a speciﬁc popula-
tion, that is, singleton gestations with short TVU CL.
Figure 3. Forest plot for the risk of the primary outcome (ie, spontaneous preterm birth<34 weeks). CI, conﬁdence interval; M-H, Mantel-Haens-
zel; df, degrees of freedom.
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This population represents one of the most at risk of
developing SPTB.15 Our meta-analysis included all stud-
ies published to date on the topic, studies of high quality
and with a low risk of bias according to the Cochrane
risk of bias tools, and included 1000 pregnant women.
Publication bias could not be assessed given the small
(<10) number of studies included. Intent-to-treat analy-
sis was used, and both random- and mixed-effects mod-
els were used when appropriate. These are key elements
that are needed to evaluate the reliability of a meta-
analysis.10
Limitations of our study are inherent to the limita-
tions of the included RCTs. Only 3 trials were included
in the meta-analysis. None of the included studies was
double-blind. More than half of the women included in
the analysis (932 out of the 1420) came from 1 large
trial, which therefore drives the summary statistics.13 All
3 trials included both low-risk (without prior SPTB) and
high-risk (with prior SPTB) women. The higher rate of
preterm birth in the control group in 1 of the trials
(26.8%)3 is not concordant with those of the control
groups of the other 2 trials.12,13 The small number of
studies did not permit meaningful stratiﬁed meta-
analyses to explore the test performance in sensitivity
analyses according to the study’s risk of bias. Similarly,
since none of the included trials stratiﬁed data by obstet-
rical history, performing subgroup analyses in women
with prior SPTB and in women without prior SPTB, as
well as by other TVU CL cutoffs, was not feasible. The
small number of available studies and the inequality of
their size could have impaired the robustness of the
meta-analysis with an increased chance of a type I error.
Implications
Different strategies have been adopted for prevention of
SPTB,16–30 including progesterone16,22 and cerclage,17,18
as well as lifestyle modiﬁcation such as smoking cessa-
tion,23 diet and aerobic exercise,24 and nutritional sup-
plements,25–30 including omega-3,25–28 folic acid,29 and
vitamins.30
The evidence supports the use of vaginal proges-
terone in singleton pregnancies with short cervix,16
while cervical cerclage seems to be beneﬁcial only in
the subgroup of women with both prior SPTB and
TVU CL 25mm.17 Interestingly, only 235 singleton
gestations without prior SPTB18 and 504 singleton ges-
tations with prior SPTB17 have been included in
randomized studies on cerclage for TVU CL 25mm,
versus 1216 and 204, respectively, for pessary. Cervical
cerclage is an invasive technique currently requiring
anesthesia and the operating room. Therefore, growing
interest has focused on pessary for prevention of
SPTB. Cervical pessary is relatively noninvasive, is easy
to use, does not require anesthesia, can be used in an
outpatient clinic setting, and is easily removed when
necessary.19 The exact mechanism for possible efﬁcacy
of the cervical pessary to prevent SPTB in women
with a short CL is not completely clear. Vitsky et al in
1961 ﬁrst suggested that the incompetent cervix is
aligned centrally, with no support except the nonresis-
tant vagina.20 A lever pessary, therefore, would change
the inclination of the cervical canal, directing it more
posteriorly. In doing so, the weight of the pregnancy
would be more on the anterior lower segment.19
Another proposed mechanism is that the pessary could
strengthen the immunological barrier between the
chorioamnion-extraovular space and the vaginal micro-
biological ﬂora, as cerclage has been postulated to
do.3,21
Most recently, a new large randomized study—the
OPPTIMUM study—did not ﬁnd signiﬁcant effect of
vaginal progesterone in prevention of PTB in 1228
women at risk of SPTB due to 3 major risk factors: prior
SPTB; positive fetal ﬁbronectin test; or short TVU CL
<25.31 It is noteworthy that the OPPTIMUM study
was underpowered to detect a meaningful difference
between vaginal progesterone and placebo in the sub-
group of women with a short cervix, with a post hoc sta-
tistical power of only 26% to detect a 23% reduction in
the risk of SPTB <34 weeks. Individual-level meta-anal-
yses are being performed currently, and the sample sizes
for women with prior SPTB and other subgroups may
have been underpowered, too. In a meta-analysis of 5
RCTs, including the OPPTIMUM trial, Romero et al
showed that in women with a mid-trimester short CL,
progesterone is associated with a signiﬁcant reduction in
the risk of preterm delivery and neonatal morbidity and
mortality, without any deleterious effects on neurodeve-
lopmental outcome.32
There are at least 4 potential reasons why the pes-
sary was effective in the Goya3 trial and not in the Hui12
and Nicolaides13 trials. First, training for pessary inser-
tion might have differed, even slightly. In the Nicolaides
study,13 it is stated that “the research-team members
who inserted the pessaries had received practical training
in the placement of the device,” while the Goya study
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states that “the central team instructed the other centers
in the use of the pessary.”3 This study reported another
mechanism to conﬁrm that the pessary was placed cor-
rectly: All of the patients had a TVU to conﬁrm correct
placement of the pessary,3 while in Nicolaides study a
transvaginal ultrasound was done every 4 weeks to assess
cervical length. Of note, there was no speciﬁc training
provided regarding pessary insertion in the Hui trial.12
Second, the Nicolaides trial13 included multiple sites,
some of which did not enroll many subjects, raising the
possibility of lesser experience with pessary placement
and management. Third, there were more women with
prior SPTB in the Nicolaides trial13 (154/932 [16.5%])
compared to the Goya3 (41/380 [10.8%]) and Hui12
(9/108 [8.3%]) trials. Pessary may be more effective in
singleton gestations with short CL and without prior
SPTB, but this issue could not be further analyzed given
the fact that no prior SPTB and prior SPTB subgroup
analyses were reported in any of the trials.3,12,13 Last, in
the Nicolaides trial, the administration of vaginal proges-
terone to most women with CL 15mm could have
masked any beneﬁt from the cervical pessary in this
group.13 It might be noted that Goya et al3 and Hui
et al12 did not reported any data regarding the use of the
progesterone.
In conclusion, prophylactic use of Arabin pessary in
singleton gestations with a short TVU CL 25mm at
200 to 246 weeks does not prevent SPTB or improve
perinatal outcome. Given the small sample size, further
trials are needed.
Individual patient data meta-analysis may clarify
whether cervical pessary may be beneﬁcial in subgroups,
such as only singleton gestations without prior SPTB or
singleton gestations with prior SPTB, or by different
TVU CL cutoffs other than25mm.
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